TRMT9B and neoplasm: Finally, we show that loss of hTRM9L in certain tumours can be exploited as a potential chemotherapeutic target since its absence renders tumour cells sensitive to aminoglycoside antibiotics, which induce misincorporation at specific codons leading to protein damage and selective tumour cell killing.